AbL Diagnostics SA Total Liabilities
AbL Diagnostics SA total liabilities. Based on the latest financial reports, AbL Diagnostics SA (ABLD) has total liabilities worth €5.32 Million EUR (≈ $6.22 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AbL Diagnostics SA (ABLD) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of AbL Diagnostics SA (2007–2025)
Total liabilities of AbL Diagnostics SA from 2007 to 2025. This chart illustrates how AbL Diagnostics SA's total liabilities have evolved over time, based on quarterly financial data.
AbL Diagnostics SA Competitors by Total Liabilities
The table below lists competitors of AbL Diagnostics SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Indah Prakasa Sentosa PT Tbk
JK:INPS
|
Indonesia | Rp283.96 Billion |
|
Feerum S.A.
WAR:FEE
|
Poland | zł42.23 Million |
|
Vanfund Urban Investment & Development Co Ltd
SHE:000638
|
China | CN¥153.23 Million |
|
RMB Holdings Ltd
JSE:RMH
|
South Africa | ZAC46.00 Million |
|
Dominari Holdings Inc.
NASDAQ:DOMH
|
USA | $35.52 Million |
|
Inbest Prime VI Inmuebles Socimi SA
MC:YINB6
|
Spain | €24.04K |
|
Yuyu Pharma
KO:000220
|
Korea | ₩63.32 Billion |
|
BII Railway Transportation Technology Holdings Company Limited
F:CN6
|
Germany | €1.97 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down AbL Diagnostics SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is AbL Diagnostics SA's balance sheet.
Liquidity & Leverage Metrics
AbL Diagnostics SA Total Liabilities Ratios Explained
AbL Diagnostics SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how AbL Diagnostics SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for AbL Diagnostics SA (2007–2025)
The table below shows the annual total liabilities of AbL Diagnostics SA from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.32 Million ≈ $6.22 Million |
+23.11% |
| 2024-12-31 | €4.32 Million ≈ $5.05 Million |
-46.86% |
| 2023-12-31 | €8.14 Million ≈ $9.51 Million |
-5.99% |
| 2022-12-31 | €8.65 Million ≈ $10.12 Million |
+9081.14% |
| 2021-12-31 | €94.26K ≈ $110.20K |
+420.78% |
| 2020-12-31 | €18.10K ≈ $21.16K |
-84.70% |
| 2019-12-31 | €118.31K ≈ $138.32K |
-80.07% |
| 2018-12-31 | €593.64K ≈ $694.03K |
+346.04% |
| 2017-12-31 | €133.09K ≈ $155.60K |
-17.93% |
| 2016-12-31 | €162.18K ≈ $189.60K |
-79.83% |
| 2015-12-31 | €804.11K ≈ $940.09K |
+460.64% |
| 2014-12-31 | €143.43K ≈ $167.68K |
-34.43% |
| 2013-12-31 | €218.75K ≈ $255.74K |
+151.83% |
| 2012-12-31 | €86.86K ≈ $101.55K |
-21.84% |
| 2011-12-31 | €111.14K ≈ $129.94K |
+2.38% |
| 2010-12-31 | €108.56K ≈ $126.91K |
+90.10% |
| 2009-12-31 | €57.10K ≈ $66.76K |
+12.32% |
| 2008-12-31 | €50.84K ≈ $59.44K |
-1.20% |
| 2007-12-31 | €51.46K ≈ $60.16K |
-- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more